D.E. Shaw & Co
ACRV icon

D.E. Shaw & Co’s Acrivon Therapeutics ACRV Stock Holding History

D.E. Shaw & Co’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31,939
Closed -$157K – 4296
2023
Q4 		$157K Sell
31,939
-14,811
-32% -$78.2K ﹤0.01% 3918
2023
Q3 		$447K Sell
46,750
-160
-0.3% -$1.85K ﹤0.01% 3471
2023
Q2 		$608K Sell
46,910
-14,986
-24% -$181K ﹤0.01% 3340
2023
Q1 		$785K Buy
+61,896
New +$1.04M ﹤0.01% 3324

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's ACRV Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Acrivon Therapeutics (ACRV) in Q1 2024, closing a stake of 31,939 shares — an estimated $157K sold.

D.E. Shaw & Co first reported a position in ACRV in Q1 2023 and held it in 4 quarters. The position peaked at $785K in Q1 2023. 48 funds tracked by Wall St. Rank hold ACRV as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Acrivon Therapeutics position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 31,939 Acrivon Therapeutics shares in Q1 2024, an estimated $157K.
  • D.E. Shaw & Co first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 4 quarters.
  • D.E. Shaw & Co's Acrivon Therapeutics position peaked at $785K in Q1 2023.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.